The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Utility of Routine Post-Therapy Surveillance Imaging in Diffuse Large B-Cell Lymphoma
Open accessAbstract
Purpose: We examined the utility of post-therapy surveillance imaging in a large, prospectively enrolled cohort of patients with diffuse large B-cell lymphoma (DLBCL) from the United States and confirmed our results in an independent cohort of patients from France. Methods: Patients with newly diagnosed DLBCL and treated with anthracycline-based immunochemotherapy were identified from the Molecular Epidemiology Resource (MER) of the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence and the Léon Bérard Cancer Center, Lyon, France. In those with relapse, details at relapse and outcomes were abstracted from records. Results: 680 individuals with DLBCL were identified from the MER, 552 (81%) of whom achieved remission after induction. 112 of the 552 patients (20%) suffered a relapse. The majority (64%) of relapses were identified before a scheduled follow-up visit. Surveillance imaging detected DLBCL relapse before clinical manifestations in nine out of 552 patients (1.6%) observed after therapy. In the Lyon cohort, imaging identified asymptomatic DLBCL relapse in four out of 222 patients (1.8%). There was no difference in survival after DLBCL relapse in patients detected at scheduled follow-up versus before scheduled follow-up in both the MER (P = .56) and Lyon cohorts (P = .25). Conclusion: The majority of DLBCL relapses are detected outside of planned follow-up, with no difference in outcome in patients with DLBCL detected at a scheduled visit compared with patients with relapse detected outside of planned follow-up. These data do not support the use of routine surveillance imaging for follow-up of DLBCL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Morton, L. M., Turner, J. J., Cerhan, J. R., Linet, M. S., Treseler, P. A., Clarke, C. A., Jack, A., Cozen, W., Maynadié, M., Spinelli, J. J., et al. (2007) · Blood · doi:10.1182/blood-2006-11-051672 · Cited by 387 · cited 1×
“In the United States, approximately 15,000 new cases of DLBCL are diagnosed each year.(1,2) Standard-of-care treatment is anthracyclinebased immunochemotherapy (most commonly, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).”
BackgroundSelf-citation
Metadata
- Authors
- Thompson, C. A., Ghesquieres, H., Maurer, M. J., Cerhan, J. R., Biron, P., Ansell, S. M., Chassagne-Clément, C., Inwards, D. J., Gargi, T., Johnston, P. B., Nicolas-Virelizier, E., Macon, W. R., Peix, M., Micallef, I. N., Sebban, C., Nowakowski, G. S., Porrata, L. F., Weiner, G. J., Witzig, T. E., Habermann, T. M., & Link, B. K.
- Venue
- Journal of Clinical Oncology
- Published
- 2014-11-01
- Volume
- 32
- Issue
- 31
- Pages
- 3506-3512
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2115637639
- Cited by
- 175
- References
- 1
- FWCI
- 13.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Utility of Routine Post-Therapy Surveillance Imaging in Diffuse Large B-Cell Lymphoma. https://app.cochat.ai/papers/10.1200/jco.2014.55.7561
- The paper
- Thompson, C. A., Ghesquieres, H., Maurer, M. J., Cerhan, J. R., Biron, P., Ansell, S. M., Chassagne-Clément, C., Inwards, D. J., Gargi, T., Johnston, P. B., Nicolas-Virelizier, E., Macon, W. R., Peix, M., Micallef, I. N., Sebban, C., Nowakowski, G. S., Porrata, L. F., Weiner, G. J., Witzig, T. E., . . . Link, B. K. (2014). Utility of Routine Post-Therapy Surveillance Imaging in Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2014.55.7561
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
